Research programme: tyrosine kinase inhibitors - Wyeth
Latest Information Update: 07 Aug 2009
At a glance
- Originator Wyeth
- Mechanism of Action Protein tyrosine kinase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 07 Aug 2009 Discontinued - Preclinical for Cancer in USA (PO)
- 04 May 2005 Preclinical trials in Cancer in USA (PO)